STOCK TITAN

[8-K] Newell Brands Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Celularity Inc. (Nasdaq: CELU) filed an 8-K reporting that on 21 Jul 2025 it entered into a new secured financing.

  • Issued a $6.812 million promissory note to a single investor. The note carries 2% annual interest and matures on 21 Mar 2026 (≈8 months).
  • The note is secured by a first-priority lien on all company assets.
  • The investor also received a warrant for 3.7 million Class A shares exercisable at $2.528 per share for five years; the window is tolled if CFIUS clearance is needed.
  • A portion of the proceeds must be used to fully retire Celularity’s March 2023 loan from C.V. Starr & Co.

The low-cost debt improves near-term liquidity and allows repayment of legacy borrowing, but the blanket lien and short maturity could restrict flexibility. Full warrant exercise would raise up to ≈$9.3 million in equity yet materially dilute existing holders.

Celularity Inc. (Nasdaq: CELU) ha presentato un modulo 8-K comunicando che il 21 luglio 2025 ha stipulato un nuovo finanziamento garantito.

  • Ha emesso una nota di debito da 6,812 milioni di dollari a un singolo investitore. La nota prevede un interesse annuo del 2% e scade il 21 marzo 2026 (circa 8 mesi).
  • La nota è garantita da un privilegio di prima priorità su tutti i beni della società.
  • L'investitore ha inoltre ricevuto un warrant per 3,7 milioni di azioni di Classe A esercitabili a 2,528 dollari per azione per cinque anni; il periodo di esercizio è sospeso se è necessaria l'approvazione CFIUS.
  • Una parte dei proventi deve essere utilizzata per estinguere completamente il prestito di Celularity del marzo 2023 con C.V. Starr & Co.

Il debito a basso costo migliora la liquidità a breve termine e consente il rimborso dei prestiti preesistenti, ma il privilegio generale e la breve scadenza potrebbero limitare la flessibilità. L'esercizio completo del warrant potrebbe raccogliere fino a circa 9,3 milioni di dollari in equity, diluendo però in modo significativo gli azionisti attuali.

Celularity Inc. (Nasdaq: CELU) presentó un formulario 8-K informando que el 21 de julio de 2025 celebró un nuevo financiamiento garantizado.

  • Emitió un pagaré por 6.812.000 dólares a un solo inversor. El pagaré tiene un interés anual del 2% y vence el 21 de marzo de 2026 (aproximadamente 8 meses).
  • El pagaré está garantizado con un gravamen de primera prioridad sobre todos los activos de la empresa.
  • El inversor también recibió un warrant por 3,7 millones de acciones Clase A ejercitable a 2,528 dólares por acción durante cinco años; el período se suspende si se requiere la aprobación de CFIUS.
  • Una parte de los fondos debe usarse para cancelar completamente el préstamo de Celularity de marzo de 2023 con C.V. Starr & Co.

La deuda de bajo costo mejora la liquidez a corto plazo y permite el pago de préstamos anteriores, pero el gravamen general y el vencimiento corto podrían limitar la flexibilidad. El ejercicio completo del warrant podría recaudar hasta aproximadamente 9,3 millones de dólares en capital, aunque diluiría considerablemente a los accionistas actuales.

Celularity Inc. (나스닥: CELU)는 2025년 7월 21일 새로운 담보 금융 계약을 체결했다고 8-K 보고서를 제출했습니다.

  • 단일 투자자에게 681만 2천 달러 약속어음을 발행했습니다. 약속어음은 연 2% 이자율이 적용되며 만기는 2026년 3월 21일(약 8개월)입니다.
  • 이 약속어음은 회사 자산 전체에 대한 최우선 담보권으로 보장됩니다.
  • 투자자는 또한 3.7백만 주의 클래스 A 주식 워런트를 받았으며, 주당 2.528달러에 5년간 행사할 수 있습니다; CFIUS 승인 필요 시 행사 기간은 연장됩니다.
  • 수익금 일부는 Celularity가 2023년 3월 C.V. Starr & Co.로부터 받은 대출을 완전히 상환하는 데 사용해야 합니다.

저비용 부채는 단기 유동성을 개선하고 기존 차입금을 상환할 수 있게 하지만, 전면 담보권과 짧은 만기는 유연성을 제한할 수 있습니다. 워런트를 전부 행사하면 최대 약 930만 달러의 자본을 조달할 수 있으나 기존 주주들의 지분 희석이 상당할 것입니다.

Celularity Inc. (Nasdaq : CELU) a déposé un formulaire 8-K indiquant qu'elle a conclu un nouveau financement garanti le 21 juillet 2025.

  • Émission d'une billet à ordre de 6,812 millions de dollars à un investisseur unique. Le billet porte un intérêt annuel de 2% et arrive à échéance le 21 mars 2026 (environ 8 mois).
  • Le billet est garanti par un privilège de premier rang sur tous les actifs de la société.
  • L'investisseur a également reçu un warrant portant sur 3,7 millions d'actions de classe A, exerçable à 2,528 dollars par action pendant cinq ans ; la période d'exercice est suspendue si une autorisation CFIUS est nécessaire.
  • Une partie des fonds doit être utilisée pour rembourser intégralement le prêt de mars 2023 de Celularity auprès de C.V. Starr & Co.

Cette dette à faible coût améliore la liquidité à court terme et permet de rembourser les emprunts antérieurs, mais le privilège global et la courte échéance pourraient limiter la flexibilité. L'exercice complet du warrant pourrait lever jusqu'à environ 9,3 millions de dollars en fonds propres, tout en diluant significativement les actionnaires actuels.

Celularity Inc. (Nasdaq: CELU) hat am 21. Juli 2025 eine neue besicherte Finanzierung abgeschlossen und dies in einem 8-K gemeldet.

  • Es wurde ein Schuldschein über 6,812 Millionen US-Dollar an einen einzelnen Investor ausgegeben. Der Schuldschein trägt 2 % Jahreszins und läuft am 21. März 2026 ab (ca. 8 Monate).
  • Der Schuldschein ist durch eine vorrangige Grundschuld auf alle Unternehmensvermögen besichert.
  • Der Investor erhielt außerdem einen Warrant über 3,7 Millionen Stammaktien der Klasse A, ausübbar zu 2,528 US-Dollar pro Aktie für fünf Jahre; die Ausübungsfrist wird ausgesetzt, falls eine CFIUS-Freigabe erforderlich ist.
  • Ein Teil der Erlöse muss zur vollständigen Tilgung des im März 2023 aufgenommenen Darlehens von Celularity bei C.V. Starr & Co. verwendet werden.

Die kostengünstige Verschuldung verbessert die kurzfristige Liquidität und ermöglicht die Rückzahlung von Altschulden, jedoch könnten die umfassende Grundschuld und die kurze Laufzeit die Flexibilität einschränken. Die vollständige Ausübung des Warrants könnte bis zu etwa 9,3 Millionen US-Dollar Eigenkapital einbringen, würde aber die bestehenden Anteilseigner erheblich verwässern.

Positive
  • $6.8 million of fresh capital secured at a low 2% interest rate
  • Proceeds earmarked to retire existing Starr loan, potentially reducing overall cost of capital
  • Warrants could generate an additional $9.3 million in equity if exercised
Negative
  • Issuance of 3.7 million warrants introduces dilution risk for current shareholders
  • Promissory note is secured by all company assets, limiting collateral for future borrowing
  • Short March 2026 maturity may create near-term refinancing pressure

Insights

TL;DR: Low-cost cash bolsters runway but secured note plus warrants add leverage and dilution.

The 2% coupon is attractively priced, suggesting the investor perceives limited credit risk. Repaying the Starr loan may lower aggregate financing cost and remove covenants tied to that facility. However, pledging all assets reduces optionality for future secured borrowings, and the March 2026 maturity forces refinancing within the next nine months. The 3.7 million warrants—~9% of basic shares outstanding based on recent filings—create overhang until exercised or expired. Net impact: modestly positive for liquidity, neutral for valuation.

TL;DR: Transaction shifts debt structure but adds collateral risk and potential equity dilution.

The blanket lien means lenders now sit ahead of unsecured creditors, elevating recovery risk for other stakeholders. Short-dated maturity concentrates refinancing risk into H1 2026. While the warrant strike sits 35-40% above recent market levels, any sustained rally would trigger dilution. Overall, the filing is not materially adverse but does heighten capital-structure complexity.

Celularity Inc. (Nasdaq: CELU) ha presentato un modulo 8-K comunicando che il 21 luglio 2025 ha stipulato un nuovo finanziamento garantito.

  • Ha emesso una nota di debito da 6,812 milioni di dollari a un singolo investitore. La nota prevede un interesse annuo del 2% e scade il 21 marzo 2026 (circa 8 mesi).
  • La nota è garantita da un privilegio di prima priorità su tutti i beni della società.
  • L'investitore ha inoltre ricevuto un warrant per 3,7 milioni di azioni di Classe A esercitabili a 2,528 dollari per azione per cinque anni; il periodo di esercizio è sospeso se è necessaria l'approvazione CFIUS.
  • Una parte dei proventi deve essere utilizzata per estinguere completamente il prestito di Celularity del marzo 2023 con C.V. Starr & Co.

Il debito a basso costo migliora la liquidità a breve termine e consente il rimborso dei prestiti preesistenti, ma il privilegio generale e la breve scadenza potrebbero limitare la flessibilità. L'esercizio completo del warrant potrebbe raccogliere fino a circa 9,3 milioni di dollari in equity, diluendo però in modo significativo gli azionisti attuali.

Celularity Inc. (Nasdaq: CELU) presentó un formulario 8-K informando que el 21 de julio de 2025 celebró un nuevo financiamiento garantizado.

  • Emitió un pagaré por 6.812.000 dólares a un solo inversor. El pagaré tiene un interés anual del 2% y vence el 21 de marzo de 2026 (aproximadamente 8 meses).
  • El pagaré está garantizado con un gravamen de primera prioridad sobre todos los activos de la empresa.
  • El inversor también recibió un warrant por 3,7 millones de acciones Clase A ejercitable a 2,528 dólares por acción durante cinco años; el período se suspende si se requiere la aprobación de CFIUS.
  • Una parte de los fondos debe usarse para cancelar completamente el préstamo de Celularity de marzo de 2023 con C.V. Starr & Co.

La deuda de bajo costo mejora la liquidez a corto plazo y permite el pago de préstamos anteriores, pero el gravamen general y el vencimiento corto podrían limitar la flexibilidad. El ejercicio completo del warrant podría recaudar hasta aproximadamente 9,3 millones de dólares en capital, aunque diluiría considerablemente a los accionistas actuales.

Celularity Inc. (나스닥: CELU)는 2025년 7월 21일 새로운 담보 금융 계약을 체결했다고 8-K 보고서를 제출했습니다.

  • 단일 투자자에게 681만 2천 달러 약속어음을 발행했습니다. 약속어음은 연 2% 이자율이 적용되며 만기는 2026년 3월 21일(약 8개월)입니다.
  • 이 약속어음은 회사 자산 전체에 대한 최우선 담보권으로 보장됩니다.
  • 투자자는 또한 3.7백만 주의 클래스 A 주식 워런트를 받았으며, 주당 2.528달러에 5년간 행사할 수 있습니다; CFIUS 승인 필요 시 행사 기간은 연장됩니다.
  • 수익금 일부는 Celularity가 2023년 3월 C.V. Starr & Co.로부터 받은 대출을 완전히 상환하는 데 사용해야 합니다.

저비용 부채는 단기 유동성을 개선하고 기존 차입금을 상환할 수 있게 하지만, 전면 담보권과 짧은 만기는 유연성을 제한할 수 있습니다. 워런트를 전부 행사하면 최대 약 930만 달러의 자본을 조달할 수 있으나 기존 주주들의 지분 희석이 상당할 것입니다.

Celularity Inc. (Nasdaq : CELU) a déposé un formulaire 8-K indiquant qu'elle a conclu un nouveau financement garanti le 21 juillet 2025.

  • Émission d'une billet à ordre de 6,812 millions de dollars à un investisseur unique. Le billet porte un intérêt annuel de 2% et arrive à échéance le 21 mars 2026 (environ 8 mois).
  • Le billet est garanti par un privilège de premier rang sur tous les actifs de la société.
  • L'investisseur a également reçu un warrant portant sur 3,7 millions d'actions de classe A, exerçable à 2,528 dollars par action pendant cinq ans ; la période d'exercice est suspendue si une autorisation CFIUS est nécessaire.
  • Une partie des fonds doit être utilisée pour rembourser intégralement le prêt de mars 2023 de Celularity auprès de C.V. Starr & Co.

Cette dette à faible coût améliore la liquidité à court terme et permet de rembourser les emprunts antérieurs, mais le privilège global et la courte échéance pourraient limiter la flexibilité. L'exercice complet du warrant pourrait lever jusqu'à environ 9,3 millions de dollars en fonds propres, tout en diluant significativement les actionnaires actuels.

Celularity Inc. (Nasdaq: CELU) hat am 21. Juli 2025 eine neue besicherte Finanzierung abgeschlossen und dies in einem 8-K gemeldet.

  • Es wurde ein Schuldschein über 6,812 Millionen US-Dollar an einen einzelnen Investor ausgegeben. Der Schuldschein trägt 2 % Jahreszins und läuft am 21. März 2026 ab (ca. 8 Monate).
  • Der Schuldschein ist durch eine vorrangige Grundschuld auf alle Unternehmensvermögen besichert.
  • Der Investor erhielt außerdem einen Warrant über 3,7 Millionen Stammaktien der Klasse A, ausübbar zu 2,528 US-Dollar pro Aktie für fünf Jahre; die Ausübungsfrist wird ausgesetzt, falls eine CFIUS-Freigabe erforderlich ist.
  • Ein Teil der Erlöse muss zur vollständigen Tilgung des im März 2023 aufgenommenen Darlehens von Celularity bei C.V. Starr & Co. verwendet werden.

Die kostengünstige Verschuldung verbessert die kurzfristige Liquidität und ermöglicht die Rückzahlung von Altschulden, jedoch könnten die umfassende Grundschuld und die kurze Laufzeit die Flexibilität einschränken. Die vollständige Ausübung des Warrants könnte bis zu etwa 9,3 Millionen US-Dollar Eigenkapital einbringen, würde aber die bestehenden Anteilseigner erheblich verwässern.

false000081445300008144532025-08-012025-08-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 1, 2025
NEWELL BRANDS INC.
(Exact name of registrant as specified in its charter)
Delaware1-960836-3514169
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
5 Concourse Parkway NE, 8th Floor,
Atlanta, Georgia 30328
(Address of principal executive offices including zip code)
(770) 418-7000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASSTRADING SYMBOLNAME OF EXCHANGE ON WHICH REGISTERED
Common stock, $1 par value per shareNWLNasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 2.02.    Results of Operations and Financial Condition.
On August 1, 2025, Newell Brands Inc. (the “Company”) issued a press release, including additional financial information, to report the Company’s earnings for the quarter ended June 30, 2025, which is attached to this report as Exhibit 99.1.
The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, regardless of any general incorporation language in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit
No.
Exhibit Description
99.1
Press Release dated August 1, 2025, issued by Newell Brands Inc. and Additional Financial Information.
101Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEWELL BRANDS INC.
Dated: August 1, 2025
By:
/s/ Mark J. Erceg
Mark J. Erceg
Chief Financial Officer

3


Exhibit 99.1
NEWELL BRANDS INC.

Press Release, dated August 1, 2025 issued by Newell Brands Inc., and Additional Financial Information
4

FAQ

How much new debt did Celularity (CELU) issue?

The company issued a $6,812,230 promissory note.

What are the terms of the new CELU note?

It bears 2% annual interest, is secured by all assets, and matures on 21 Mar 2026.

How many warrants were granted and at what price?

The investor received 3,700,000 warrants exercisable at $2.528 per share.

How long are the CELU warrants exercisable?

Five years from issuance, with extension to five years after any required CFIUS clearance.

What will Celularity do with the note proceeds?

A portion will fully settle the March 2023 loan from C.V. Starr & Co.

Is the financing expected to dilute existing shareholders?

Yes. Exercising the 3.7 million warrants would expand the share count, diluting current ownership.
Newell Brands

NASDAQ:NWL

NWL Rankings

NWL Latest News

NWL Latest SEC Filings

NWL Stock Data

2.39B
415.30M
0.45%
97.37%
4.49%
Household & Personal Products
Plastics Products, Nec
Link
United States
ATLANTA